Faslodex, Fulvestrant (fulvestrant) is a small molecule pharmaceutical. Fulvestrant was first approved as Faslodex on 2002-04-25. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against estrogen receptor beta and estrogen receptor. In addition, it is known to target G-protein coupled estrogen receptor 1. Faslodex's patents are valid until 2034-05-17 (FDA).
|Drug Class||Estrogen antagonists|